Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 41 (1) , 252-259
- https://doi.org/10.1016/j.jpedsurg.2005.10.047
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic CancerJournal of Clinical Oncology, 2004
- The Conundrum Posed by Cellular Heterogeneity in Analysis of Human NeuroblastomaJNCI Journal of the National Cancer Institute, 2004
- The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell lineCarcinogenesis: Integrative Cancer Research, 2004
- Insulin-like growth factor-I signaling in human neuroblastoma cellsOncogene, 2004
- Constitutively Active NFκB Is Required for the Survival of S-type NeuroblastomaJournal of Biological Chemistry, 2002
- Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activationBiochemical Pharmacology, 2002
- Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactionsBiochemical Journal, 2000
- Current aspects of biology, risk assessment, and treatment of neuroblastomaSeminars in Surgical Oncology, 1999
- Multidrug resistance in human neuroblastoma cellsJournal of Pediatric Surgery, 1991
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985